ArticleFrontiers in oncology2026

Evolution from KRAS G12C-mutant to ALK fusion-positive stage IV lung adenocarcinoma following immune checkpoint inhibitor therapy: a case report.

Feng Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.